©TheCanadian Journal ofUrology™: International Supplement, April 2014
63
MostaghelANDLin
20.ChiKN,TolcherA,LeePetal.Effectofabirateroneacetateplus
prednisoneon thepharmacokineticsofdextromethorphanand
theophylline in patients with metastatic castration-resistant
prostatecancer.
CancerChemotherPharmacol
2013;71(1):237-244.
21.Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular
genetics of CYP2D6: clinical relevance with focus on
psychotropicdrugs.
Br JClinPharmacol
2002;53(2):111-122.
22.Fitzpatrick JM,deWitR.Taxanemechanismsofaction:potential
implications for treatment sequencing inmetastaticcastration-
resistant prostate cancer.
EurUrol
2013;July 25. Epub aheadof
print.
23.GanL,ChenS,WangYetal. Inhibitionof theandrogenreceptor
asanovelmechanismof taxolchemotherapy inprostatecancer.
CancerRes
2009;69(21):8386-8394.
24.Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of
abiraterone acetate against metastatic castration-resistant
prostate cancer progressing after docetaxel and enzalutamide
(MDV3100).
AnnOncol
2013;24(7):1807-1812.
25.SchraderAJ, BoegemannM,OhlmannCHet al. Enzalutamide
incastration-resistantprostatecancerpatientsprogressingafter
docetaxel and abiraterone.
EurUrol
2014;65(1):30-36.
26.Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-
induced blockade to nuclear accumulation of the androgen
receptorpredictsclinicalresponses inmetastaticprostatecancer.
CancerRes
2011;71(18):6019-6029.
27.Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM,
Kyprianou N. Tubulin-targeting chemotherapy impairs
androgen receptor activity in prostate cancer.
Cancer Res
2010;70(20):7992-8002.
28.Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity
of docetaxel following treatment with the CYP17A1 inhibitor
abiraterone: clinical evidence for cross-resistance?
Ann Oncol
2012;23(11):2943-2947.
29.MostaghelEA,MarckB,PlymateSetal.Resistance toCYP17A1
inhibition with abiraterone in castration resistant prostate
cancer: Induction of steroidogenesis and androgen receptor
splicevariants.
ClinCancerRes
2011;17(18):5913-5925.
30.Cai C, Chen S, Ng P et al. Intratumoral de novo steroid
synthesis activates androgen receptor in castration resistant
prostatecancerand isupregulatedby treatmentwithCYP17A1
inhibitors.
CancerRes
2011;71(20):6503-6513.
31.CaffoO, PalermoA, VecciaAet al. Biochemical and objective
response to abiraterone acetate withdrawal: incidence and
clinical relevance of a new scenario for castration-resistant
prostate cancer.
Urology
2013;82(5):1090-1093.
32.Gauthier H, Bousquet G, Pouessel D, Culine S. Abiraterone
acetate withdrawal syndrome: does it exist?
Case Rep Oncol
2012;5(2):385-387.
33.Mostaghel EA, Nelson PS, Lange P et al. Targeted androgen
pathwaysuppression in localizedprostatecancer:arandomized
clinical trial. J
ClinOncol
2013;Dec 9. Epub aheadof print.
34.Taplin M, Montgomery RB, Logothetis C et al. Effect of
neoadjuvant abiraterone acetate (AA) plus leuprolide acetate
(LHRHa) onPSA, pathological complete response (pCR), and
near pCR in localized high-risk prostate cancer (LHRPC):
Resultsofarandomizedphase IIstudy.ASCOAnnualMeeting
2012;Chicago, Illinois:Abstract 4521.